TITLE

HEPTARES DEPLOYS STARS FOR SCREENING GPCR DRUG TARGETS

PUB. DATE
May 2011
SOURCE
Worldwide Biotech;May2011, Vol. 23 Issue 5, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on Heptares Therapeutics Ltd.'s use of Heptares StaR technology on G-protein-coupled receptors (GPCR) study. The StaR technology allowed the company to obtain GPCR resolutions with both Biophysical Mapping and X-ray crystallography methods, which was deemed impossible using the old method of fragment-based drug discovery (FBDD). The journal "Nature Reviews Drug Discovery" published the importance of structural information of the target when a drug is being developed.
ACCESSION #
60242739

 

Related Articles

  • HEPTARES EXTENDS GLOBAL PATENT PROTECTION.  // Biotech Financial Reports;Jan2015, Vol. 22 Issue 1, p4 

    The article focuses on multiple key patents granted to Heptares Therapeutics Ltd. in the U.S. related to its G protein-coupled receptors-focused drug discovery platform. The patents granted by the U.S. Patent Office covers Heptares technology platform for development of thermostabilised G...

  • HEPTARES COLLABORATES WITH PFIZER ON DRUG DISCOVERY.  // Worldwide Biotech;Jan2016, Vol. 28 Issue 1, p2 

    The article reports on a strategic drug discovery collaboration entered into by Heptares Therapeutics, a subsidiary of pharmaceutical firm Sosei Group Corp., with pharmaceutical firm Pfizer Inc. to research and develop potential new medicines based on G protein-coupled receptor (GPCR), as of...

  • Heptares Raises $30M Series A to Boost Therapeutic Pipeline. Moran, Nuala // BioWorld International;2/25/2009, Vol. 14 Issue 8, p1 

    The article reports on the first round of formal funding held by Heptares Therapeutics Ltd. in Great Britain. The company has a platform technology StaR which makes it possible to discover and develop drugs against G-protein-coupled receptors that are acknowledged to be important targets but...

  • Heptares Raises $30M for Therapeutic Pipeline.  // Bioworld Week;3/2/2009, Vol. 17 Issue 9, p4 

    The article reports on the decision of Heptares Therapeutics Ltd. to raise £21 million in its first round of formal funding for therapeutic pipeline in London, England. The money will be used to fund Heptares for three years to develop its own pipeline of small-molecule drug candidates using...

  • Heptares and Takeda Initiate Drug Discovery Collaboration. Hobbs, Heather // International Labmate;2011, Vol. 36 Issue 4, p63 

    The article focuses on a two-year drug discovery collaboration formed by Heptares Therapeutics and Takeda Pharmaceutical Co. that is focused on a single G-protein coupled receptor (GPCR).

  • Takeda Offers $106.3M to Back Heptares' Schizophrenia Leads. Moran, Nuala // BioWorld International;4/13/2011, Vol. 16 Issue 15, p1 

    The article reports on a deal signed by Heptares Therapeutics Ltd. with Takeda Pharmaceutical Co. for the study of a G-protein coupled receptor (GPCR) that is involved in schizophrenia. According to Heptares' Malcolm Weir, another deal could be signed between the two firms involving their...

  • Heptares Spun Out of MRC To Become A Standalone. Moran, Nuala // BioWorld International;9/5/2007, Vol. 12 Issue 36, p4 

    The article reports that Heptares Therapeutics Ltd. has been spun out by the Great Britain's Medical Research Council (MRC) to capitalize on new techniques for determining the structure of G protein-couple receptors (GPCRs) without the need to crystallize them first. Malcolm Weir, who heads the...

  • HEPTARES & MEDIMMUNE COMPLETE ANTIBODY DISCOVERY.  // Worldwide Biotech;Mar2014, Vol. 26 Issue 3, p1 

    The article reports on Heptares Therapeutics' completion of the research phase of its antibody discovery collaboration with MedImmune. It explains that Heptares has delivered thermostabilized G protein-coupled receptors (GPCR) called StaR proteins for MedImmune's drug targets. The company has...

  • Heptares' GPCR Platform Lands Cubist Collaboration. Moran, Nuala // BioWorld Today;1/ 8/2013, Vol. 24 Issue 5, p2 

    The article reports on the deal of Heptares Therapeutics Ltd. with Cubist Pharmaceuticals Inc. for its G protein-coupled receptor (GPCR) technology. It mentions that Heptares will receive $5.5 million up front and $4 million for research fund for the first target under the deal. Moreover, it...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics